Ikuko Kishida
Overview
Explore the profile of Ikuko Kishida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
281
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hattori S, Suda A, Kishida I, Miyauchi M, Shiraishi Y, Noguchi N, et al.
BMC Psychiatry
. 2023 Mar;
23(1):135.
PMID: 36869320
Background: Distinct oral atypical antipsychotics have different effects on autonomic nervous system (ANS) activity. Among them, oral aripiprazole has been linked to dysfunction of the ANS in schizophrenia. Long-acting injectable...
2.
Sakurai H, Yasui-Furukori N, Suzuki T, Uchida H, Baba H, Watanabe K, et al.
Pharmacopsychiatry
. 2021 Jan;
54(2):60-67.
PMID: 33434943
Introduction: Conventional treatment guidelines of schizophrenia do not necessarily provide solutions on clinically important issues. Methods: A total of 141 certified psychiatrists of the Japanese Society of Clinical Neuropsychopharmacology evaluated...
3.
Sakurai H, Kato M, Yasui-Furukori N, Suzuki T, Baba H, Watanabe K, et al.
Bipolar Disord
. 2020 Jun;
22(8):822-830.
PMID: 32558145
Objectives: The aim of this study was to develop a consensus guideline by certified experts of the Japanese Society of Clinical Neuropsychopharmacology on the psychopharmacological treatment for bipolar disorders I...
4.
Hattori S, Suda A, Miyauchi M, Shiraishi Y, Saeki T, Fukushima T, et al.
BMC Psychiatry
. 2020 Feb;
20(1):72.
PMID: 32070304
Background: Use of the antipsychotic drug olanzapine by patients with schizophrenia is associated with autonomic nervous system (ANS) dysfunction. It is presumed that there are interindividual differences in ANS dysfunction...
5.
Sakurai H, Uchida H, Kato M, Suzuki T, Baba H, Watanabe K, et al.
J Affect Disord
. 2020 Feb;
266:626-632.
PMID: 32056937
Background: Clinically relevant issues in the real-world treatment of depression have not always been captured by conventional treatment guidelines. Methods: Certified psychiatrists of the Japanese Society of Clinical Neuropsychopharmacology were...
6.
Hattori S, Kishida I, Suda A, Kawanishi C, Miyauchi M, Shiraishi Y, et al.
Heliyon
. 2019 Aug;
5(7):e02151.
PMID: 31384687
Background: People with depression have autonomic function disturbances. In Japan, workers who take leave due to depression often undergo a work-focused intervention program called the return to work (RTW) program...
7.
Suda A, Hattori S, Kishida I, Miyauchi M, Shiraishi Y, Fujibayashi M, et al.
Neuropsychiatr Dis Treat
. 2018 Oct;
14:2361-2366.
PMID: 30271152
Objective: Long-acting injections (LAIs) of antipsychotics show distinct pharmacokinetic profiles from oral antipsychotics (OAPs). Although there may be differences in adverse event frequency, any differences in their effects on autonomic...
8.
Hattori S, Suda A, Kishida I, Miyauchi M, Shiraishi Y, Fujibayashi M, et al.
Compr Psychiatry
. 2018 Aug;
86:119-122.
PMID: 30118994
Background: Patients with schizophrenia have a higher mortality risk than the general population. Additionally, the autonomic nervous system (ANS) activity of patients with schizophrenia is lower and more dysfunctional than...
9.
Hattori S, Suda A, Kishida I, Miyauchi M, Shiraishi Y, Fujibayashi M, et al.
BMC Psychiatry
. 2018 Jul;
18(1):231.
PMID: 30016952
Background: There are interindividual differences in the adverse effects of atypical antipsychotics, which include autonomic nervous system (ANS) dysfunction. Accordingly, to clarify the interindividual differences in the adverse effects of...
10.
Hattori S, Suda A, Kishida I, Miyauchi M, Shiraishi Y, Fujibayashi M, et al.
Schizophr Res
. 2017 Dec;
197:574-576.
PMID: 29191720
No abstract available.